Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Active, not recruiting1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

active_not_recruiting133%
completed133%
unknown133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_3

The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants

NCT06200844
unknownphase_3

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E

NCT05958771
completedphase_2

Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia

NCT03602053

Clinical Trials (3)

Showing 3 of 3 trials
NCT06200844Phase 3

The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants

Active Not Recruiting
NCT05958771Phase 3

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E

Unknown
NCT03602053Phase 2

Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3